This analysis uncovers the heterogeneous treatment effect in survival data, suggesting novel methods improve estimates by integrating trial and real-world data.
The heterogeneous treatment effect plays a crucial role in precision medicine. There is evidence that real-world data, even subject to biases, can be employed as supplementary evidence for randomized clinical trials to improve the statistical efficiency of the heterogeneous treatment effect estimation. In this paper, for survival data with right censoring, we consider estimating the heterogeneous treatment effect, defined as the difference of the treatment-specific conditional restricted mean survival times given covariates, by synthesizing evidence from randomized clinical trials and the real-world data with possible biases. We define an omnibus bias function to characterize the effect of biases caused by unmeasured confounders, censoring, and outcome heterogeneity, and further, identify it by combining the trial and real-world data. We propose a penalized sieve method to estimate the heterogeneous treatment effect and the bias function. We further study the theoretical properties of the proposed integrative estimators based on the theory of reproducing kernel Hilbert space and empirical process. The proposed methodology outperforms the approach solely based on the trial data through simulation studies and an integrative analysis of the data from a randomized trial and a real-world registry on early-stage non-small-cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: